Inhibition of lysine acetyltransferase KAT6 in ER+HER2− metastatic breast cancer: a phase 1 trial
Toru Mukohara(Juntendo University), Patricia LoRusso(Yale Cancer Center)
Cited by 50
Related Papers
Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced Cancers
|Clinical Cancer Research|2010|250
Randomized clinical trial of a brief and extensive dyadic intervention for advanced cancer patients and their family caregivers
|Psycho-Oncology|2012|238
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study
|Journal of Clinical Oncology|2024|158
Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study
|Seoul National University Open Repository (Seoul National University)|2021|95